

## Immuno-Oncology Profiling Services

### Efficacy Profiling of Cancer Immunotherapies

- Our cancer immunotherapy platform is based on 3D co-culture models from patient-derived micro-tumors and autologous T lymphocytes
- We have successfully established 3D co-culture models for a variety of cancer types (incl. renal cell carcinoma, NSCLC, malignant melanoma, colorectal carcinoma; other entities in progress)
- 3D micro-tumor cultures are ready for compound testing in 96-well format within 2 weeks after isolation from tumor tissue
- All assays are amenable to mono and combinatorial dose-response testing (i.e., by targeted and cell-based approaches, antibodies, etc.)

### Compound Testing in Patient-Derived 3D Tumor/Immune Cell Models

- Selective live cell labeling, cytotoxicity analyses
- Time-resolved high-content analysis of micro-tumor infiltration by T lymphocytes
- Proteomics add-ons:  
Multiplex Luminex cytokine assays,  
DigiWest protein profiling
- Genomics add-ons:  
Multiplex RT-qPCR panel assays
- Studies are offered on a fee-for-service basis and are fully customizable

